Open AccessSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
Author(s) -
M. Farouk Chughlay,
Karen I. Barnes,
Myriam El Gaaloul,
Nada Abla,
Jörg J. Möhrle,
Paul Griffin,
Paul van Giersbergen,
Stephanie E. Reuter,
Hayley B. Schultz,
Anita Kress,
Peter Tapley,
Rebecca A. Webster,
Timothy Wells,
James S. McCarthy,
Bridget E. Barber,
Louise Marquart,
Michelle J. Boyle,
Christian R. Engwerda,
Stephan Chalon
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01584-21
Subject(s) - ruxolitinib , medicine , pharmacokinetics , pharmacodynamics , pharmacology , adverse effect , parasitemia , placebo , clinical trial , artemisinin , artemether/lumefantrine , janus kinase inhibitor , malaria , randomized controlled trial , confidence interval , phases of clinical research , oncology , immunology , janus kinase , neutropenia , crossover study
Despite repeated malaria infection, individuals living in areas where malaria is endemic remain vulnerable to reinfection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with antimalarial therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom